MSK-ACCESS (ACCESS129)

Overview

Targeted (129 genes) sequencing of cfDNA via MSK-ACCESS on Illumina HiSeq sequencers — canonical cBioPortal gene panel ACCESS129.

Used by

  • PMID:36357680 — at MSK, plasma sequencing with MSK-ACCESS was offered from 10 June 2019 onward in the ctDNA-guided NSCLC cohort, alongside MSK-IMPACT tissue sequencing; both assays use matched white-blood-cell sequencing to remove clonal hematopoiesis and germline variants PMID:36357680.
  • PMID:37682528 — used for serial cfDNA profiling (>15,000x coverage, 0.1% VAF threshold) of 27 erdafitinib-treated urothelial carcinoma (BLCA/UTUC) patients, identifying putative on-treatment resistance mutations in TP53 (n=5), AKT1 (n=1), and second-site FGFR3 kinase-domain alleles including V553M and N540S PMID:37682528.
  • PMID:39289779 — MSK-ACCESS plasma ctDNA was compared with CSF ctDNA (MSK-IMPACT) in 31 patients with CNS tumors; 54% of alterations were shared between CSF and plasma, but CSF VAFs were markedly higher (median 36.4% vs. 2.3%, p < 0.01), demonstrating the superiority of CSF over plasma for CNS tumor monitoring PMID:39289779.
  • PMID:37769223 — MSK-ACCESS (129-gene panel, ~200,000x raw coverage with error suppression) used to profile cfDNA from 53 plasma samples of 51 advanced HCC patients; detected genomic alterations in 90.6% of samples; complemented by matched tumor tissue profiled with MSK-IMPACT in 72.5% of patients PMID:37769223.
  • PMID:39147831 — MSK-ACCESS used to sequence plasma from 4,141 (discovery) and 1,426 (validation) patients across all cancer types; ctDNA detection was independently associated with VTE risk (HR 2.49); random survival forest model incorporating ACCESS ctDNA variables achieved c-index 0.74 for VTE prediction PMID:39147831.
  • MSK-ACCESS liquid biopsy panel used for ctDNA profiling of patient 12 in a KRASG12C-mutant colorectal cancer cohort, detecting acquired KRAS amplification (KRAS/Cen12 ratio 13.2 at progression vs 1.8 pretreatment) PMID:36355783

Notes

  • Sequencing operational metrics in the NSCLC ctDNA cohort: only 37/1,919 (2%) ctDx Lung or MSK-ACCESS samples failed, vs 13% of tissue sequencing attempts; turnaround from blood draw to report was 11 days (IQR 9–14) for MSK-ACCESS/ctDx Lung vs 33 days for MSK-IMPACT PMID:36357680.

Sources

This page was processed by crosslinker on 2026-05-06. - PMID:36355783

This page was processed by crosslinker on 2026-05-06.